News Release Details

UroGen Pharma to Present at Upcoming Investor Conferences

May 18, 2022 at 8:00 AM EDT

PRINCETON, N.J.--(BUSINESS WIRE)--May 18, 2022-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will present at the following healthcare conferences:

H.C. Wainwright & Co. Global Investment Conference

  • Wednesday, May 25 at 11:00 a.m. ET

Jefferies Healthcare Conference

  • Thursday, June 9 at 1:00 p.m. ET

Webcasts of both the H.C. Wainwright & Co. and Jefferies presentations will be available via the Investors section of UroGen’s website, www.urogen.com. A replay of each webcast will be available on the Company’s website for approximately 30 days.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

INVESTOR CONTACT:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA CONTACT:
Cindy Romano
UroGen Corporate Communications
cindy.romano@urogen.com
908-963-7827

Source: UroGen Pharma Ltd.